Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — World Sleep 2023

10 slides from Centessa Pharmaceuticals's conference presentation, Oct 25, 2023

  1. Slide 1: Disclaimer and forward-looking statements

    This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv

  2. Slide 2: ORX750, an Oral Selective Orexin Receptor 2 Agonist, Promotes Wakefulness and Reduces Cataplexy

    ORX750, an Oral Selective Orexin Receptor 2 Agonist, Promotes Wakefulness and Reduces Cataplexy in the Orexin/Ataxin-3 Mouse Sarah Wurts Black, Ph.D. October 25th World Sleep 2023, Rio de Janeiro, Brazil

  3. Slide 3: ORX750 summary of preclinical findings

    • ORX750 is a novel, full OX2R agonist designed using high resolution crystal and cryo-EM structures • ORX750 potently activated the OX2R with an EC50 of 0.11 nM and 9,800-fold selectivity over OX1R • Oral administration of ORX750 achieved maximal wake times in highly predictive Atax and DTA mouse m

  4. Slide 4: ORX750 potency and selectivity at OX2R

    Log concentration (M) Activation (% total) • Activation pattern was indistinguishable from OXA with lack of biased agonism1 • No significant differences in OX2R potency were observed across species2 • No significant pharmacological activity observed in GPCR selectivity and in vitro safety panels3 4

  5. Slide 5: High potency at native mouse OX2R

    High potency at native mouse OX2R ORX750 depolarized1 and increased firing rates2 of histaminergic neurons in the TMN 5 -50 mV 2 min 20 mV Application Period ORX750 (30 nM) Whole cell recordings of histaminergic neurons in ventral TMN in mouse brain slices • ORX750 EC50 5 nM; OXA EC50 32 nM • TMN=tu

  6. Slide 6: ORX750 increases wakefulness in narcolepsy mouse models

    6 • Age at first dose 20-22 wks in orexin/ataxin-3 (Atax) and 23-27 wks (7 wks after removal of doxycycline chow) in orexin/tTA;tetO diphtheria toxin fragment A (DTA) mice; males used • EEG, EMG recorded using intraperitonially implanted telemeters with video and manually scored in 10-sec epochs; do

  7. Slide 7: ORX750 reduces cataplexy in narcolepsy mouse models

    7 • Manually scored 10-sec epochs by consensus criteria (Scammell, T et al., SLEEP 2009;32(1):111) in mice housed with running wheels; dosing at start of dark period • If no cataplexy was observed during the 6 h test window, the maximum possible latency was assigned (360 min); mice without cataplexy

  8. Slide 8: ORX750 effects on EEG power during wakefulness

    8 • Increase in EEG power in gamma frequency associated with enhanced alertness (Cantero, J.L., et al., NeuroImage, 2004;22:1271) • Data normalized as the percent of the mean power across all frequency bands in 6 h recording from 10-sec, artifact-free wakefulness epochs of manually scored EEG • * p

  9. Slide 9: ORX750 consolidates wakefulness in Atax and wild type mice

    9 • Age at first dose was 16-20 wks in male Atax mice and WT colony mates; mice dosed at 5 h after lights on • * p < 0.05 vs. 0 mg/kg, Holm-Sidak multiple comparisons test following RM-ANOVA per mouse model in counterbalanced design Wake bout duration (mean sec during 1 h post dose) Wake bout occurr

  10. Slide 10: Summary: ORX750 as potential best-in-class narcolepsy treatment

    • ORX750 is a novel, full OX2R agonist designed using high resolution crystal and cryo-EM structures • ORX750 potently activated the OX2R with an EC50 of 0.11 nM and 9,800-fold selectivity over OX1R • Oral administration of ORX750 achieved maximal wake times in highly predictive Atax and DTA mouse m

Centessa Pharmaceuticals — World Sleep 2023 on 6ix